APR 14, 2020 8:15 AM PDT

Immunotherapy Shows Promise, Destroys Metastatic Brain Tumors

WRITTEN BY: Tara Fernandez

 

Lung cancer is the leading cause of death in both men and women in the U.S., with smokers bearing an elevated risk of the disease. This form of cancer can be asymptomatic in the early stages, escaping detection until it has progressed to an advanced stage, where it can spread, or metastasize, to other regions in the body.

A team of cancer researchers at Yale have published their findings on a promising therapeutic strategy targeting a subset of lung cancer patients with brain metastases. For these patients, which account for about a quarter of all those diagnosed with lung cancer, radiation is often prescribed — a treatment that has significant side effects. The study was published in The Lancet Oncology.

Corresponding author, Sarah Goldberg, Assistant Professor of Medical Oncology at the Yale School of Medicine works as a clinician in the Thoracic Oncology group at the Yale Cancer Center and conducts research on new therapeutic strategies against lung cancer. 

 

 

Here, a cohort of 42 patients were selected for the trial, all of which had brain metastases that had not responded to radiology or had not received treatment. The immunotherapy tested was pembrolizumab (sold under the trade name Keytruda®), a monoclonal antibody administered to patients whose cancers expressed the biomarker PD-L1. Significantly, this checkpoint inhibitor therapy extended patient survival and had drastically fewer side effects than radiation.

Speaking on the significance of the study, Goldberg said, “We have clearly shown, for the first time, that brain metastasis responds to a targeted immunotherapy treatment for lung cancer.” 

“In general, we found that the benefit offered by pembrolizumab to the lungs in patients with advanced lung cancer was mirrored in control of their brain tumors. The brain and body response were the same.”

Interestingly, patients whose brain tumors expressed high levels of PD-L1 experienced longer lasting positive effects from the pembrolizumab therapy, a finding that warrants further investigation.

These results point to a need to reassess the gold standard therapeutic strategies for lung cancer patients with brain metastases. “It might make sense for some patients to try a checkpoint inhibitor first to treat both their lung cancer and brain metastasis. Radiation could follow, if necessary,” said Goldberg.

 



Sources: Yale News, The Lancet Oncology.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
MAY 23, 2020
Microbiology
The FDA Yanks Some COVID-19 Antibody Tests From the Market
MAY 23, 2020
The FDA Yanks Some COVID-19 Antibody Tests From the Market
The massive demand for diagnostic testing led the FDA to open a short window for many testing products to go to market w ...
JUN 04, 2020
Immunology
Tissue Stiffness Regulates Immune Responses
JUN 04, 2020
Tissue Stiffness Regulates Immune Responses
  Cells are remarkably sensitive to the mechanical properties of their environment, changing their behavior as a re ...
JUN 20, 2020
Cell & Molecular Biology
Antibodies Isolated From COVID-19 Patients Show Therapeutic Potential
JUN 20, 2020
Antibodies Isolated From COVID-19 Patients Show Therapeutic Potential
Communities worldwide are emerging from lockdowns due to the SARS-CoV-2 pandemic virus, and cases are rising.
AUG 14, 2020
Microbiology
Seasonal Flu Vaccine Immunity Probably Wears Off
AUG 14, 2020
Seasonal Flu Vaccine Immunity Probably Wears Off
From year to year, the influenza virus mutates and swaps genes with other flu viruses, and we need a new vaccine. But th ...
SEP 23, 2020
Immunology
Gene That Fuels Antibody Factories Discovered
SEP 23, 2020
Gene That Fuels Antibody Factories Discovered
Antibodies are Y-shaped proteins that play a central role in the immune system’s arsenal of germ-busting weapons. ...
SEP 11, 2020
Immunology
Study Reveals Tumor Defense Mechanism... And How to Beat It
SEP 11, 2020
Study Reveals Tumor Defense Mechanism... And How to Beat It
  P53 is an infamous process gene at the core of the development of tumors.  When P53  functional, it pau ...
Loading Comments...